RXII Stock News 3.17 05/13/2014 19:38:30 Rxi Pharmaceuticals

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Rxi Pharmaceuticals (RXII) 3.17 $RXII

RXi Pharmaceuticals Announces Positive Results with RXI?109 in the Eyes of Cynomolgus Monkeys as Part of a Dose Range Finding Study
PR Newswire - Fri May 02, 6:02AM CDT
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced results from the assessment of connective tissue growth factor (CTGF) protein levels following intravitreal injection, of RXI--109 in the eyes of cynomolgus monkeys, as part of a dose-range finding study to build the Company's ophthalmology franchise.

RXi Pharmaceuticals begins phase 2a study of RXI-109 in keloid patient
M2 - Wed Apr 30, 4:02AM CDT
Biotechnology company RXi Pharmaceuticals (NasdaqCM:RXII) revealed on Tuesday that the first patient has been admitted in its second Phase 2a study of RXI-109 for the prevention of keloid recurrence.

RXi Pharmaceuticals Announces Initiation of Phase 2a Keloid Study
PR Newswire - Tue Apr 29, 12:03PM CDT
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the first patient has enrolled in their Phase 2a study (RXI-109-1401) with RXI-109 for the prevention of keloid recurrence. RXI-109 is an sd-rxRNA® compound that targets connective tissue growth factor (CTGF) and is being developed for the treatment of abnormal dermal scars, such as hypertrophic scars and keloids, in conjunction with scar or keloid revision surgery. Phase 1 studies have shown that RXI-109 is safe and well tolerated. In addition, RXI-109 was shown to reduce CTGF mRNA in line with its mechanism of action by up to 50% in healthy volunteers with the doses tested. Excessive production of CTGF is considered a major cause of abnormal scarring, such as hypertrophic scars and keloids.

RXi Pharmaceuticals to Present at ARVO 2014 Annual Meeting
PR Newswire - Mon Apr 28, 6:02AM CDT
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies today announced that the Company will present at the Association for Research in Vision and Ophthalmology (ARVO) 2014 Annual Meeting.

RXi Pharmaceuticals Enters into Financing Facility with Lincoln Park Capital
PR Newswire - Tue Apr 22, 2:29PM CDT
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering and developing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, announced today that it has entered into a purchase agreement (the "Purchase Agreement" with Lincoln Park Capital Fund, LLC ("LPC", a Chicago-based institutional investor, whereby LPC is committed to purchase up to an aggregate of up to $20 million shares of RXi common stock over a 30-month term. The funds, in part, will serve to advance research and development activities for the Company's ophthalmological pre-clinical drug pipeline.

RXi Pharmaceuticals Reports Full Year 2013 Financial Results
PR Newswire - Fri Mar 28, 3:45PM CDT
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today reported its financial results for the full year 2013, and provided a business update.

RXi Pharmaceuticals Announces Upcoming Presentations
PR Newswire - Fri Mar 14, 6:02AM CDT
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced upcoming presentations at the 6th Ocular Diseases and Drug Development Conference, the 72nd Annual Meeting of the American Academy of Dermatology ("AAD" and the Keystone Symposia Meeting, Fibrosis: From Bench to Bedside.

RXi Pharmaceuticals Granted Key Patent Related to Self-Delivering Technology for the Treatment of Fibrotic Disorders
PR Newswire - Wed Mar 05, 6:02AM CST
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that it has been granted a patent by the U.S. Patent and Trademark Office on its unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment of fibrosis. The patent covers the use of sd-rxRNAs targeting CTGF, including RXI--109, for the treatment of fibrotic disorders. U.S. Patent Number 8,664,189, will expire in 2029. The Notice of Allowance was released on January 14, 2014 for this patent.

RXi Pharmaceuticals to Present at the 26th Annual ROTH Conference
PR Newswire - Tue Mar 04, 6:02AM CST
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Company's President & CEO, Dr. Geert Cauwenbergh, will present at the 26th Annual ROTH Conference on Tuesday, March 11, 2014 at 4:30pm PST. Dr. Cauwenbergh will discuss the development of RXI-109, a self-delivering RNAi compound designed to reduce dermal scarring, as well as business development opportunities with RXi's sd-rxRNA® technology platform.

RXi Pharmaceuticals (RXII) Jumps: Stock Adds 28.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 7:51AM CST
RXi Pharmaceuticals Corporation was a big mover last session, as its shares rose almost 29% on the day.

RXi Pharmaceuticals to Present at the 24th Annual Wall Street Analyst Forum
PR Newswire - Mon Feb 24, 6:02AM CST
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Company's President & CEO, Dr. Geert Cauwenbergh, will present at the 24th Annual Wall Street Analyst Forum on Monday, March 3, 2014 at 12:50pm EST. Dr. Cauwenbergh will discuss the development of RXI-109, a self-delivering RNAi compound designed to reduce dermal scarring, as well as business development opportunities with RXi's sd-rxRNA® technology platform.

OTC Markets Group Congratulates RXI Pharmaceuticals on NASDAQ Listing
PR Newswire - Tue Feb 11, 9:00AM CST
OTC Markets Group Inc. (OTCQX: OTCM) congratulates RXI Pharmaceuticals Corp. (NASDAQ: RXII) on its approval to list on the NASDAQ Capital Market. RXI is moving to NASDAQ from OTCQX®, the best marketplace for qualified companies.

RXi Pharmaceuticals Announces Listing on NASDAQ Capital Market
PR Newswire - Tue Feb 11, 6:02AM CST
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, announced today that the Company received approval by The NASDAQ Stock Market LLC's ("NASDAQ" Listing Qualification Department to list its common stock on the NASDAQ Capital Market. The Company's common stock will commence trading under the same ticker symbol, "RXII," on the NASDAQ Capital Market effective at the opening of trading on Tuesday, February 11, 2014.

RXi Pharmaceuticals to Present at the 16th Annual BIO CEO & Investor Conference
PR Newswire - Mon Feb 03, 6:02AM CST
RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Company's President & CEO, Dr. Geert Cauwenbergh, will present at the 16th Annual BIO CEO & Investor Conference on Tuesday, February 11, 2014 at 11:30am EST. Dr. Cauwenbergh will discuss the development of RXI-109, a self-delivering RNAi compound designed to reduce dermal scarring, as well as business development opportunities with RXi's sd-rxRNA® technology platform.

RXI Pharmaceuticals Could Benefit from Biotech Industry Dynamics
ACCESSWIRE - Fri Jan 24, 9:06AM CST
RNA interference ("RNAi" therapeutics may have experienced some hurdles in the past, but favorable clinical results have boosted their profile in recent months. With new data supporting both safety and efficacy, larger pharmaceutical companies are starting to regain confidence in the sector. These dynamics have sparked a number of new deals and collaborations that have boosted industry valuations and opened the door to new opportunities.

RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders
PR Newswire - Tue Jan 14, 6:02AM CST
RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that it received the Notice of Allowance from the United States Patent and Trademark Office on its unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment of fibrosis. The patent covers the use of sd-rxRNAs targeting CTGF, including RXI-109, for the treatment of fibrotic disorders. The patent, once issued, will be scheduled to expire in 2029.

NIH Data Sharing Projects Could Accelerate RNAi Field
ACCESSWIRE - Wed Jan 08, 10:16AM CST
The RNA industry could receive a significant boost this year after the National Institute of Health ("NIH" announced a data-sharing collaboration with Life Technologies Corp. (NASDAQ: LIFE) in December. Under the deal, large-scale information covering the biochemical makeup of small interfering RNA ("siRNA" molecules will be made publicly available to help scientists better understand how genes affect disease.

RXi Pharmaceuticals to Present at the Biotech Showcase(TM) 2014
PR Newswire - Mon Jan 06, 6:02AM CST
RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Company's President and Chief Executive Officer, Dr. Geert Cauwenbergh, will present at the Biotech Showcase(TM) 2014 conference on Tuesday, January 14, 2014 at 9:30AM PST. Dr. Cauwenbergh will discuss the development of RXI-109, a self-delivering RNAi compound designed to reduce dermal scarring, as well as business development opportunities with RXi's sd--rxRNA® technology platform.

Surgical Scar Market Is Ripe for Innovation
ACCESSWIRE - Wed Dec 18, 10:15AM CST
Scarring is an inevitable consequence of dermal wounds - such as those incurred during routine surgeries - that has a profound impact on physical appearance and psychological well-being. Despite high demand for therapies that prevent or reduce dermal scarring, there are few treatment options approved by the U.S. Food & Drug Administration ("FDA", which has led to significant investor appetite for companies targeting the space. For instance, Oculus Innovative Sciences, Inc. (NASDAQ: OCLS) recently doubled in price after receiving FDA 510(k) approval for its Microcyn Scar Management HydroGel on December 4, 2013.

RXi Pharmaceuticals Announces mRNA Data of an Additional Cohort in the Second Phase 1 Multi-Dose Study with RXI-109, Extending the Dose Response Following Treatment in the Initial 2-week Period
PR Newswire - Wed Dec 04, 7:05AM CST
RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced additional results from their second placebo-controlled Phase 1 study with RXI--109, an sd-rxRNA® compound that targets Connective Tissue Growth Factor (CTGF), and is being developed for the treatment of abnormal dermal scars such as hypertrophic scars and keloids in conjunction with scar revision surgery.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pickleman’s Chips Turn a Side Into a Brand Signal Now

Updated Category News Views 74

A bag of dill pickle chips is hardly earthshaking news, yet this one says plenty about where fast-casual brands are trying to compete. Pickleman’s Gourmet Cafe is launching its own proprietary chip line with non-GMO ingredients, sunflower oil, a pared-down ingredient profile, and a flavor that actually fits the name on the door. More importantly, a portion of each...

Continue Reading
Two Xinjiang Histories Arrive With a Clear State Lens

Updated Category News Views 27

Dusty chronology rarely carries this much present-day weight. Two books released in Beijing on September 2, The History of China's Xinjiang Region and The Religious History in China's Xinjiang Region, are presented as the most comprehensive works on the subject yet produced by Chinese scholars. That is a sizable claim, and it deserves to be read with both attention and a...

Continue Reading
Italian Wine Faces U.S. Slump and New Market Openings

Updated Category News Views 154

American demand has put a cork in the easy story, and Italian wine producers cannot pretend otherwise. In the first nine months of 2026, U.S. imports of Italian wine dropped 18.4% by value. That is painful because the United States remains Italy's largest destination market by value, not some side shelf that can be ignored until conditions improve. Still, the broader U.S....

Continue Reading
NKT’s Q3 Margin Holds Up as Capacity Spending Bites

Updated Category News Views 54

Steel, copper and giant cable drums do not make for a pretty quarterly story, but NKT’s numbers have a sturdier backbone than the headline revenue dip suggests. The company delivered EUR 111 million of operational EBITDA in Q3 2026, down from EUR 119 million a year earlier, while its margin at standard metal prices edged up to 16.6% from 16.4%. That is not fireworks. It...

Continue Reading
Markley’s Lowell Campus Turns Data Land Into Arboretum

Updated Category News Views 279

Server halls rarely get credited with restoring a landscape, which is why Markley’s Lowell campus caught my eye. On November 18, 2026, the company said its Lowell data center campus had earned Level I arboretum accreditation from the ArbNet Arboretum Accreditation Program. ArbNet describes itself as the only international accreditation program specifically for arboreta,...

Continue Reading
Sysco's Northern California Labor Deal Gets Bigger

Updated Category News Views 159

One hundred forty-four drivers may not rattle a giant food distributor by themselves, but labor agreements have a habit of growing legs. Sysco's Northern California and Nevada regional contract has added members from Teamsters Locals 386 and 431, bringing its coverage above 1,100 workers. For investors watching Sysco, this is less about one afternoon's headline and more...

Continue Reading
Rare Stellar Merger Validates RIT Theory in Nature

Updated Category News Views 82

One star swallowed another’s orbit, and astronomy finally caught the evidence. That is the plain-English punch of the observation called AT 2025abao in the Andromeda Galaxy, and it is a meaningful one for Jason Nordhaus and his colleagues at Rochester Institute of Technology. On Nov. 18, research published in Nature validated a scenario Nordhaus’s team had predicted...

Continue Reading
AI Search Is Squeezing Clicks, Not Killing Content Yet

Updated Category News Views 90

A search result that answers the question before earning a click is a nasty little disruption, and marketers are plainly feeling around for solid ground. Goodfirms surveyed 192 content marketing professionals for its 2026 Content Engagement Metrics report, and the headline is more resilient than the prevailing panic: 66.3% said organic website traffic grew over the prior...

Continue Reading
EmTech AI 2027 Puts AI Ambitions Through Reality Test

Updated Category News Views 50

A three-day gathering cannot settle AI's biggest arguments, but MIT Technology Review has picked the right fight for EmTech AI 2027: make the industry face a Reality Test. The conference runs May 11–13, 2027, at MIT's campus and online, and that theme lands because the AI conversation has spent plenty of time admiring the engine while skipping the ugly maintenance bill....

Continue Reading
Cineverse Sets Wolf Creek Return for March 19, 2027

Updated Category News Views 34

A sunburned serial killer is heading back to theaters, and Cineverse has finally put a date on it: March 19, 2027. WOLF CRE3K, formerly called Wolf Creek: Legacy, brings John Jarratt back as Mick Taylor for the third film in the Australian horror franchise. For NASDAQ:CNVS investors, this is not the kind of announcement that lets anyone pencil in revenue with a straight...

Continue Reading

Top 5 Most Recently Viewed Articles

Portal26 Welcomes Rick O'Rourke as New Chief Revenue Officer

Updated Category News Views 222

Portal26 Appoints Rick O'Rourke as Chief Revenue Officer Portal26, a leading generative AI adoption management platform, has officially appointed Rick O'Rourke as its new Chief Revenue Officer (CRO). Bringing over 20 years of expertise, O'Rourke's impressive track record is well-aligned with the company’s mission to innovate and thrive within the rapidly-evolving...

Continue Reading
Biocodex Microbiota Foundation's $50K Grant Opens for 2026

Updated Category News Views 286

Let’s Talk Microbiome Research Had a look at this, huh? The Biocodex Microbiota Foundation is rolling out $50,000 for gut microbiome studies in 2026. They’re celebrating ten years of giving researchers a leg-up, with $500K dished out to date. It’s good stuff, depending on how you slice it. This isn’t just free cash; it’s a bid to push boundaries in health and...

Continue Reading
Discover Triple Paste's New Products for Healthy Skin

Updated Category News Views 119

Experience Healthy, Glowing Skin with Triple Paste The winter months can take a toll on our skin, especially for babies and new moms. Recognizing this, Advantice Health, the company behind the beloved Triple Paste® diaper rash ointments, is excited to reveal their latest additions designed to nurture and protect delicate skin. With a focus on safety and effectiveness,...

Continue Reading
Celebrating Sarah Valentini: A Trailblazer in Entrepreneurship

Updated Category News Views 633

Sarah Valentini: A Beacon of Innovation and Leadership In the ever-evolving landscape of entrepreneurship, recognition stands as a testament to ambition and dedication. This year marks a significant milestone as the Entrepreneur Of The Year program celebrates its 40th anniversary, highlighting leaders who are not only ambitious but are redefining the future with their...

Continue Reading
Future Outlook of the Asset Performance Management Market

Updated Category News Views 177

Asset Performance Management Market: Growth Projections The global Asset Performance Management Market is witnessing remarkable growth. The market size is expected to rise significantly, projecting an increase from approximately USD 2.16 billion to around USD 3.55 billion, reflecting a compound annual growth rate (CAGR) of 10.5% over the forecast period. This growth...

Continue Reading